EXTEND BIOSCIENCES INC
Long-acting PTH(1-34) therapeutic (EXT608) for hypoparathyroidism treatment
- Sector
- Biotech
- Headquarters
- Cambridge, MA
- Total capital
- $18.6M
- Federal grants
- $17.5M
- 19 awards · 2014–2025
- Rank in peer group#185 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $1.1M
- 2 awards · Defense
- Rank in Biotech#179 of 4373
- Granted patents
- 12
- 15 pending · first 2015
- Rank in peer group#23 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$1.0M
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$1.0M
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$2M
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$3M
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$1M
- Federal grantDefense · Phase I · Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection$162K
- Federal grantHealth and Human S · Phase I · Long-acting ghrelin for neuropathy$535K
Show 14 earlier federal awards
- Federal grantHealth and Human S · Phase I · Long-acting ghrelin for neuropathy$535K
- Federal grantHealth and Human S · Phase II · Long-acting ghrelin for the treatment of cancer cachexia$2K
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$1.9M
- Federal grantHealth and Human S · Phase II · Long-acting ghrelin for the treatment of cancer cachexia$1.4M
- Federal grantHealth and Human S · Phase I · Long-acting ghrelin for the treatment of ARS$300K
- Federal grantHealth and Human S · Phase II · Long-acting PTH for hypoparathyroidism$1.8M
- Federal grantHealth and Human S · Phase I · Ultralong-acting insulin for diabetes$350K
- Federal grantHealth and Human S · Phase II · Long-acting ghrelin for the treatment of cancer cachexia$833K
- Federal grantHealth and Human S · Phase I · Long-acting ghrelin for the treatment of ARS$300K
- Federal grantHealth and Human S · Phase I · Long acting PTH for hypoparathyroidism$307K
- Federal grantHealth and Human S · Phase I · Long acting PTH for hypoparathyroidism$307K
- Federal grantNSF · Phase II · SBIR Phase II: A platform technology that significantly improves drug delivery$742K
- Federal contractDefense · Igf::ot::igf First Monthly Technical Report$1.0M
- Federal contractDefense · Igf::ot::igf Scientific Research Services$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#185 · top 36%
- Granted patents#23 · top 4%
- Linked publications#60 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 12 granted of 27- PendingLong-acting Parathyroid HormoneUSPTOApplication 19009948
- PendingTherapeutic Vitamin D ConjugatesUSPTOApplication 18781237
- GrantedLong-acting Parathyroid HormoneUSPTOUS 12,233,115
Show all 27 patent records
- Long-acting Parathyroid HormoneJul 17, 2025 · Application 19009948Pending
- Therapeutic Vitamin D ConjugatesMay 1, 2025 · Application 18781237Pending
- Long-acting Parathyroid HormoneFeb 25, 2025 · US 12,233,115Granted
- Therapeutic Vitamin D ConjugatesSep 3, 2024 · US 12,076,366Granted
- Therapeutic Vitamin D ConjugatesSep 14, 2021 · US 11,116,816Granted
- Therapeutic Vitamin D ConjugatesJul 7, 2020 · US 10,702,574Granted
- Insulin Vitamin D ConjugatesSep 24, 2019 · US 10,420,819Granted
- Therapeutic Vitamin D ConjugatesSep 10, 2019 · US 10,406,202Granted
- Carriers For Improved Drug DeliveryFeb 6, 2018 · US 9,884,124Granted
- RNAi VITAMIN D CONJUGATESOct 17, 2017 · US 9,789,197Granted
- Insulin Vitamin D ConjugatesApr 11, 2017 · US 9,616,109Granted
- Therapeutic Vitamin D ConjugatesMar 7, 2017 · US 9,585,934Granted
- Carriers For Improved Drug DeliveryMar 22, 2016 · US 9,289,507Granted
- Vitamin D-ghrelin ConjugatesNov 3, 2015 · US 9,173,950Granted
- Insulin Vitamin D ConjugatesApplication PCTUS2015056737Pending
- Long-acting Parathyroid HormoneApplication 63464495Pending
- Long-acting Parathyroid HormoneApplication PCTUS2023032727Pending
- Therapeutic Vitamin D ConjugatesApplication PCTUS2015056723Pending
- Therapeutic Vitamin D ConjugatesApplication 62244181Pending
- Insulin Vitamin D ConjugatesApplication 62203385Pending
- Insulin Vitamin D ConjugatesApplication 62067398Pending
- RNAi VITAMIN D CONJUGATESApplication 62067400Pending
- Therapeutic Vitamin D ConjugatesApplication 62067388Pending
- Carriers For Improved Drug DeliveryApplication PCTUS2013031788Pending
- Extended Half-life G-csf And Gm-csf Vitamin D ConjugatesApplication PCTUS2020056210Pending
- Carriers For Improved Drug DeliveryApplication 61780346Pending
- Long-acting Parathyroid HormoneApplication 63412291Pending
Recent research by its founders
- RWD150 REAL-WORLD TRENDS AND PAYER DIFFERENCES IN BUPRENORPHINE DISPENSING AMONG ADOLESCENTS AND YOUNG ADULTS (AYA) WITH OPIOID USE DISORDER (OUD)20260 cites
- Impact of IL-6 and TGF-β1 on equine mesenchymal stromal cell homing gene expression20251 cites
- Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism20245 cites
Related companies, and why
- Ultima Genomics, Inc.Similar federal contract value in Biotech · $1.2M in contracts
- VIRTICI LLCSimilar federal contract value in Biotech · $1.2M in contracts
- Htg Molecular Diagnostics, IncSimilar federal contract value in Biotech · $1.2M in contracts
- ORBIS BIOSCIENCES, INC.Similar federal contract value in Biotech · $1.1M in contracts
- PARABON COMPUTATION, INC.Similar federal contract value in Biotech · $1.1M in contracts
- ANTIRADICAL THERAPEUTICS LLCSimilar federal contract value in Biotech · $1.1M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .